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AutoantibodiesThe etiology of psychotic disorders is still unknown, but in a subgroup of patients symptomsmight be caused by
an autoimmune reaction. In this study, we tested patterns of autoimmune reactivity against potentially novel
hippocampal antigens. Serum of a cohort of 621 individuals with psychotic disorders and 257 controls were
first tested for reactivity on neuropil of rat brain sections. Brain reactive sera (67 diseased, 27 healthy) were fur-
ther tested for antibody binding to glutamic acid decarboxylase (GAD) isotype 65 and 67 by cell-based assay
(CBA). A sub-cohort of 199 individuals with psychotic disorders and 152 controls was tested for the prevalence
of anti-nuclear antibodies (ANA) onHEp2-substrate aswell as for reactivity to double-strandedDNA, ribosomal P
(RPP), and cardiolipin (CL). Incubation of rat brainwith serum resulted in unidentified hippocampal binding pat-
terns in both diseased and control groups. Upon screening with GAD CBA, one of these patterns was identified as
GAD65 in one individual with schizophrenia and also in one healthy individual. Two diseased and two healthy
individuals had low antibody levels targeting GAD67 by CBA. Antibody reactivity on HEp-2-substrate was in-
creased in patients with schizoaffective disorder, but only in 3 patients did antibody testing hint at a possible di-
agnosis of systemic lupus erythematosus. Although reactivity of serum to intracellular antigens might be
increased in patients with psychotic disorder, no specific targets could be identified. GAD antibodies are very
rare and do not seem increased in serum of patients with psychotic disorders.
© 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1.108, 6229 ERMaastricht, P.O.
. Martinez-Martinez).
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The etiology of psychotic disorders is still unknown, but in a sub-
group of patients the symptoms might be caused by an autoimmune
reaction (Hoffmann et al., 2016). Early suspicions on a link between
autoimmunity and psychotic disorders were invigorated by the dis-
covery of brain reactive immunoglobulins (Heath and Krupp,
1967). Also, the increased occurrence of psychosis in autoimmune
disorders and vice versa suggests overlapping etiological factors
(Benros et al., 2014a; Benros et al., 2014b). A shared risk factor for
both diseases is the prior occurrence of infections (Benros et al.,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C. Hoffmann, S. Zong, M. Mané-Damas et al. Schizophrenia Research 228 (2021) 462–4712011). In addition, a common genetic predisposition was found for
schizophrenia and six immune system-related diseases, including
systemic lupus erythematosus (SLE) (Pouget et al., 2019). Recently,
much attention has been drawn to the role of autoantibodies
targeting neuronal surface antigens (NSAbs) in the brain of patients
with autoimmune encephalitis who often present with psychosis.
One of the proteins targeted is the N-methyl-D-aspartate receptor
(NMDAR) causing patients to develop characteristic neurologic and
psychiatric symptoms (Dalmau et al., 2011). It is clinically important
that these diseases respond very well to immunosuppressive treat-
ment indicating that any neuronal damage might be largely revers-
ible (Graus et al., 2016; Varley et al., 2017; Zandi et al., 2014).
Whether NSAbs can occur in purely psychotic patients, however, is
less clear; their prevalence varies between 0 and 11% (Bergink
et al., 2015; Endres et al., 2015; Lennox et al., 2017), possibly due
to differences in the methodology of antibody detection and patient
cohorts (Jezequel et al., 2017; Leypoldt et al., 2017; Pathmanandavel
et al., 2015). In our own studies, autoantibodies against NMDAR and
five other neuronal surface antigens in patients with a broad diag-
nostic spectrum of psychotic disorders were found to be absent
after careful cross-validation to eliminate false positives (de Witte
et al., 2015; Hoffmann et al., 2019).
In many autoimmune diseases neuropsychiatric problems are com-
mon. Within the group of systemic autoimmune rheumatic diseases
(SARD), especially SLE may have neurological manifestations, the so-
called neuro-lupus (Damoiseaux et al., 2015; Flower et al., 2017; Pego-
Reigosa and Isenberg, 2008; Unterman et al., 2011). This warrants the
testing for anti-nuclear antibodies (ANA), antibodies to double-
stranded (ds) DNA, anti-extractable nuclear antigens (ENA) (including
Ribosomal P protein (RPP)), and cardiolipin (CL) in patients with symp-
toms of psychosis. For instance, the presence of anti-RPP and anti-ds
DNA cross-reacting to NMDAR subunit 2 have been associated with in-
creased risk of neuropsychiatric symptoms in SLE (Hanly et al., 2011; Ho
et al., 2016). Antibodies in general have poor or no access to intracellular
antigen targets and are thus unlikely to bind to them and cause a direct
pathogenic effect on the function of neurons. Yet, presence of certain au-
toantibodies might still be indicative for other autoimmune disease
mechanisms (mediated by co-existing autoantibodies or autoreactive
T cells, for example) that can be targeted by immunosuppressive treat-
ment. Autoantibodies against the intracellularly located glutamic acid
decarboxylase (GAD), which is the rate-limiting enzyme in the synthe-
sis of gamma amino-butyric acid (GABA) occur in serum and CSF of pa-
tients with several neurological and endocrine syndromes. All these
syndromes are characterized by dysfunction of the GABAergic sys-
tem (Alexopoulos and Dalakas, 2013; Fouka et al., 2015; Saiz et al.,
2008) suggesting that in this case the autoantibodies are a relevant
biomarker for an autoimmune mechanism targeting this system.
GAD autoantibodies are also a biomarker for diabetes mellitus type
1, but antibodies are reported to occur in lower titers than in neuro-
logical syndromes (Nakajima et al., 2018). Notably, some GAD
antibody-positive conditions are responsive to immunosuppressive
treatment, e.g. autoimmune epilepsy, even though to a lesser extent
than patients with NSAbs (Daif et al., 2018; Vinke et al., 2018). There
is other evidence that intracellular proteins could be autoimmune
targets. In an animal model for the Stiff person syndrome, intrathecal
application of antibodies against amphiphysin, an intracellular vesic-
ular protein, leads to symptoms of reduced GABAergic transmission
(Geis et al., 2010).
Here, we further characterize the serum binding patterns on rat
brain of a cohort that tested negative for antibodies against neuro-
nal surface antigens. We extend our antigen specific search for
glutamic acid decarboxylase autoantibodies and tested for the
occurrence of systemic autoimmune rheumatic disease-related au-
toantibodies in patients with psychotic disorders and healthy indi-
viduals including anti-nuclear antibodies (ANA), and antibodies to
dsDNA, RPP and CL.4632. Methods
2.1. Study population
Samples and patient datawere collectedwithwritten informed con-
sent according to national and institutional ethical guidelines and the
Helsinki Declaration, with additional informed consent by legal repre-
sentatives for patients under age 18. The ability to provide written in-
formed consent was evaluated by a psychiatrist by a face-to-face
interview using a series of open-ended questions evaluating compre-
hension, reasoning, choicemaking and appreciation skills of the patient.
The study population represents psychotic disorders and covers poten-
tial differences in diagnosis (Table 1). This is the same population used
in our earlier study on the occurrence of NSAbs (Hoffmann et al., 2019).
The cohorts from Rotterdam and France are part of the European net-
work of national schizophrenia networks studying Gene-Environment
Interactions (EU-GEI, http://www.eu-gei.eu).
2.2. Psychiatric diagnosis
The diagnosis was established by the treating psychiatrists based
on the DSM-IV. The group of patients with psychotic disorders in-
cluded schizophrenia, schizoaffective, brief psychotic disorder,
schizophreniform, and other psychotic diagnoses, i.e. psychosis not
otherwise specified, delusional disorder, substance induced psycho-
sis, paranoid, and schizoid personality disorder.
2.3. Rat brain immunohistochemistry
Procedures were approved by the animal experiment committee at
Maastricht University as well as the central committee of animal
experiment (CCD) (WP 2016-005-001). Neuronal autoantibodies were
identified by IHC on rat brain tissue following standard methods
(Gresa-Arribas et al., 2014; Hoffmann et al., 2019; Titulaer et al.,
2014). In brief, Lewis rat brains were fixed for 1 h in 4% paraformalde-
hyde and cryoprotected in 30% sucrose solution. After blocking with
0.3% H2O2 and 5% goat serum, sections were incubated with human
serum diluted 1: 200 in 5% goat serum overnight at 4 °C. After incubat-
ing with biotinylated goat anti-human IgG Fcγ (1:3200, 109–066-008,
Jackson ImmunoResearch) for 2 h at 20 °C, tissue was incubated with
VECTASTAIN Elite ABC kit (Vector lab., # PK 6100) for 1 h at 20 °C and
the reactivity developed using diaminobenzidine. Staining included
serum samples from healthy individuals as negative controls, and
from autoimmune encephalitis patients (against various autoantigens)
as positive controls. Images were taken by the VENTANA iScan HT
slide scanner (20× objective) and observed on the screen (Ventana
Image Viewer). A grade between 0 and 3 was given based on the inten-
sity and contrast of reactivity of sera against the hippocampal neuropil.
All stainings thatwere scored 1–3 and inconclusive caseswere repeated
and validated by two independent observers of whom at least one was
blinded. Those with inconsistent results were repeated at least once
more and a final score (1 = borderline, 2 = weak positive, 3 = strong
positive) was given according to all images of one sample.
2.4. Screening anti-GAD autoantibodies with CBA
Specific antibody screening detection was performed using an in-
house CBA for glutamic acid decarboxylase isotypes 65 kDa and 67 kDa
(GAD65, GAD67). The GAD plasmids expressed human GAD65 and
GAD67 with the pCMV6-XL5 plasmid which was a kind gift from Dr.
Francesc Graus (IDIBAPS, Barcelona) (Arino et al., 2014). HEK293 cells
were plated on coverslips and transfected with 4 μg expression vectors
of the respective human antigens and expression allowed for 22–26 h.
Cells were fixed in 3.6% formaldehyde (#F006, TAAB) for 10 min and
permeabilized with 0.3% Triton-X-100 for 10 min. After blocking with
1% bovine serum albumin (BSA) for 1 h, cells were incubated with
Table 1
Demographic description of cohorts.
Cohort 1 Cohort 2 Cohort 3 Cohort 4 Cohort 5 Cohort 6
Healthy, n 13 – – – 44 200
Psychotic
disorders, n






and out- patient clinics)












































No presence of a severe
medical condition, and












as well as the absence
of infectious diseases
Time-span November 2003 to July
2007
June 2010 to May 2014 2011 to 2012. January 2007 to
December 2010
March 2014
Reference (De Hert et al., 2006) (Szoke et al., 2014) – (Schwarz et al., 2012) (Pina-Camacho et al.,
2014)
–
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the respective antigen (rabbit-anti-GAD65 (clone 7309LB, gift fromChris-
tina Hampe, 1:1000); or rabbit-anti-GAD67 (clone 10266/20B, gift from
Christina Hampe, 1:1000)) for 1 h at 20 °C. Reactivity was visualized
after incubation with secondary antibodies goat-anti-human-IgG Fcγ-
Alexa488 (#109-546-170, Jackson, 1:1000) and goat-anti-rabbit
Alexa594 (#111-585-144, Jackson, 1:1000) for 1 h at 20 °C. Screenings al-
ways included a positive control from an autoantibody positive patient
and a negative human serum control. Cover glasses were mounted onto
7 μl DAPI mounting medium (#H-1200, Vector Laboratories) and evalu-
ated by two (of which one blinded) observers independently on the
BX51 Olympus microscope for antibody reactivity. When positive, the
staining was repeated with serial dilution (1,50 up to 1,3200).
2.5. Measuring SARD-related autoantibodies
Screening of SARD-related antibodies was performed in collabora-
tion with IMMCO Diagnostics (Buffalo, New York, USA). Immunofluo-
rescent analysis (IFA) for ANAs was performed using ImmuGlo™ANA
HEp-2 kit (#1103, Immco Diagnostics, USA) according to manufactur-
er's instructions. In short, patients' sera were incubated on HEp-2 cells
in a dilution of 1:40 (in serum diluent) to allow binding of antibodies.
Bound antibodies were detected by incubation of the substrate with
fluorescein-labeled, anti-human IgG conjugate provided by the kit. Re-
actions were observed under a fluorescence microscope (NikonEclipse
50i diagnostic microscope) equipped with appropriate filters. Enzyme
Linked Immunosorbent Assay (ELISA) or line immune assays (LIAs)
were performed to test for the presence of ENA, dsDNA, CL and RPP au-
toantibodies. To this end an ELISA platewas pre-coatedwith the respec-
tive antigen(s): ENA (collectively detects, in onewell, total ENAs against
dsDNA, nDNA, histones, SS-A(Ro), SS-B(La), Sm, Sm/RNP, Scl-70, Jo-1,
and centrometric antigens, ImmuLisa™ Enhanced ANA Screen ELISA,
catalog # 5175), dsDNA (ImmuLisa™ Double stranded DNA antibody
Enhanced ELISA, #5120), RPP (IMMULisa Ribosomal P, # 4133), or CL
(ImmuLisa™ Cardiolipin IgG, IgA and IgM antibody(ACA) Enhanced
ELISAs, #5118G, #5118A and #5118M). Serumwas incubated at a dilu-
tion of 1:100. Horseradish peroxidase (HRP) conjugated anti-human
IgG was used for labelling specific antibodies. Enzyme substrate (TMB)
was then added to the wells and the presence of antibodies was de-
tected by a color change produced by the conversion of TMB substrate
to a colored reaction product. The reaction was stopped with H2SO4464and the intensity of the color change read by a spectrophotometer at
450 nm. Results are expressed in ELISA Units per milliliter (EU/ml)
and reported as positive or negative. Threshold for positivity was >50
for dsDNA and >20 EU/ml for all other antigens.
2.6. Statistics
To test for the difference of rat brain IHC and ANA indirect immuno-
fluorescence scores between the groups, we performed a non-
parametric Kruskal-Wallis test. All testswere done in IBMSPSS Statistics
version 23.0 for Windows.
3. Results
3.1. Novel hippocampal patterns of rat brain IHC are not specific for mental
disorder
In a first step, we screened 621 patients with psychotic disorders and
257 healthy individuals for the presence of NSAbs. As reported in our
previous publication, we did not identify any sera with antibodies against
NMDAR (GluN1 alone and GluN1/GluN2B), leucine-rich glioma-
inactivated1 (LGI1),α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR), or γ-aminobutyric acid receptor subunit A and B
(GABAaR, GABAbR). One serum sample (from a control participant) had
autoantibodies targeting contactin-associated protein-like 2 (Caspr2) at
a dilution 1:100 in the live version of the CBA. Further, only 2 sera
contained antibodies binding to neurons at a dilution of 1:50; one was
froma patientwith schizophrenia and onewas froma control participant,
(Hoffmann et al., 2019).
Yet, the rat brain IHC revealed some distinct hippocampal patterns,
that we present here. Several sera gave unknown patterns on the
hippocampal neuropil, suggesting that they target novel cell surface or
synaptic antigens. Hippocampal stainings with strong binding (grading
3) could be grouped according to similarity into eight patterns (see
Fig. 1, Pattern A-H). Two of these samples (indicated with * in Fig. 1)
were the sera previously reported to be reactive on live neurons
(Hoffmann et al., 2019). Pattern A was prominent and seen with five
sera (four from patients with schizophrenia and one from a control in-
dividual). This pattern gave a gradient in the dentate gyrus and synaptic
areas of the cornu ammonis (CA). With the same screening strategy for
autoantibodies against neuronal surface and synaptic antigens in
Fig. 1. Microscope images from sera positive by rat brain immunohistochemistry (IHC). Hippocampal IHC patterns graded 3 were sorted according to similarity into eight groups. Each
image represents reactivity of one serum sample. Each box represents sera with similar hippocampal immunoreactivity patterns. Images labeled with * are from sera that were also
reactive on live hippocampal neurons. Pattern F was identified as GAD65 antibody positive.
C. Hoffmann, S. Zong, M. Mané-Damas et al. Schizophrenia Research 228 (2021) 462–471patients with depression and/or anxiety we also found some novel
staining patterns on the hippocampus (Zong et al., 2020). Some of
these were overlapping with the here reported reactivity, e.g. the
here reported pattern A has similarity with the pattern C reported
for 4 patients in the study by Zong et al. Interestingly, two samples
resulting in this pattern that had higher antibody titers in that
study also tested positive on live neurons. Further the here reported
pattern C (2 schizophrenia patients, 1 healthy individual) was also
reported for 2 healthy controls labeled as pattern K by Zong et al..
Pattern D (1 schizophrenia patient, 1 control individual) was similar
to that in a previously published staining by Bergink et al. (2015)
with serum from a patient with post-partum psychosis, which was
also reactive to live neurons.
3.2. Autoantibodies against GAD65 and GAD67 are rare and do not differ
between healthy controls and disease groups
Some of the IHC positive sera might also have autoantibodies
targeting intracellular neuronal antigens. As GAD is an antigen that is re-
lated to neurological syndromes with GABA disturbances, we extended
our antigen-specific screening of all sera that were graded 1–3 andwith
CBA testing for GAD65 and GAD67 reactivity. An overview of all the au-
toantibody screening results is shown in Table 2. Two sera were found
to be reactive to GAD65 and GAD67; one of a schizophrenia patient
(Fig. 1, Pattern F) and one of a healthy participant. We further identified
4 sera reactive to GAD67 alone (at amax. dilution 1:100 or 1:200). Most
GAD67 antibodies cross-react to GAD65 as they bind to a common epi-
tope. This has been observed for antibodies occurring in patients with
diabetes as well as in neurological conditions (Gresa-Arribas et al.,4652015; Jayakrishnan et al., 2011). However, a case of cerebellar ataxia
presented with antibodies restricted to the GAD67 isotype, indicating
the possibility that there is another type of GAD67 antibodies (Guasp
et al., 2016). As there is not enough research on GAD65/67 antibody re-
activity in psychiatric disorders, we prefer not to make the assumption
of cross-reactivity.
Those sera reactive to GAD65 and GAD67 showed hippocampal re-
activity pattern specific to GAD65, which is the same pattern in e.g.
GAD antibody-positive epilepsy (Niehusmann et al., 2009). Those sera
reactive to GAD67 alone had each a different hippocampal binding pat-
tern and therefore were considered to contain neuronal autoantibodies
or autoantibodies against unknown antigens (Fig. 2). In conclusion, we
identified 2 sera reactive to GAD65 and GAD67 (Table 3).
3.3. Serum reactivity to HEp-2 substrate is increased in individuals with
schizoaffective disorder, but specific autoantibodies against dsDNA, RPP,
and CL are not
We investigated the prevalence of SARD-related autoantibodies
in sera of a sub-cohort consisting of 199 patients with psychotic
disorders, and 152 healthy individuals (Table 2). The reactivity of
sera to ANAs on HEp-2 cells was increased in individuals with
schizoaffective disordercompared to healthy individuals (Kruskal
Wallis, p = 0.011). However, the number of sera testing positive
for specific antigens (dsDNA, RPP, and CL) here was too low for rele-
vant statistical analysis. We found that 3 sera (2 schizophrenia, 1
schizoaffective disorder) were consistently positive in different di-
agnostic assays (Table A.1), so it might be relevant to examine for











No. 257 621 476 44 38 47 16
av. age 44.1 34.4 36.6 31.4 26.7 22.9 31.5
% female 47.5 39.9 39.5 61.4 34.2 36.1 18.8
Methods:
IHC rat brainb Tested, no. 257 621 476 44 38 47 16
Grade = 1, no. (%) 14 (5.4) 40 (6.4) 29 (6.1) 4 (9.1) 2 (5.3) 3 (6.4) 2 (12.5)
Grade = 2, no. (%) 8 (3.1) 13 (2.1) 10 (2.1) 2 (4.5) 1 (2.6) 0 (0) 0 (0)
Grade = 3, no. (%) 5 (1.9) 14 (2.3) 10 (2.1) 1 (2.3) 2 (5.3) 1 (2.2) 0 (0)
CBA (IHC+cohort) Tested, no. 27 67 49 7 5 3 3









Tested, no. 152 199 114 40 0 43 2
av. age 41.9 28.4 29.7 31.3 22.3 27.5
% female 49.3 41.2 37.7 57.5 37.2 66.7
ANA IFA Borderline, no. (%) Nucleus 21 (13.8) 18 (9.0) 8 (7.0) 6 (15.0) 3 (7.0) 1 (50.0)
Cytoplasm 1 (0.7) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Positive, no. (%) Nuclear 2 (1.4) 17 (8.5) 10 (8.8) 5 (12.5) 2 (4.7) 0 (0)
Cytoplasm 0 (0) 7 (3.5) 4 (3.5) 3 (7.5) 0 (0) 0 (0)
ENA ELISA Positive, no. (%) 2 (1.3) 4 (2) 2 (1.8) 2 (5.1) 0 (0)
dsDNA ELISA Positive, no. (%) 1 (0.7) 7 (3.5) 4 (3.5) 3 (7.7) 0 (0)
RPP ELISA/LIA Positive, no. (%) 9 (5.9) 7 (3.5) 5 (4.5) 2 (5.1) 0 (0)
CL ELISA Positive, no. (%) 12 (7.9) 9 (4.5) 6 (5.5) 2 (5.1) 1 (2.3)
No. (IgA/IgG/IgM) (1/5/0) (3/1/1) (1/1/1) (1/0/0) (1/0/0)
a Controls consist of 200 blood donors and 57 individuals without psychiatric diagnosis.
b Data taken from Hoffmann et al. (2019).
C. Hoffmann, S. Zong, M. Mané-Damas et al. Schizophrenia Research 228 (2021) 462–4714. Discussion
In our cohort of patients with psychotic disorders only two samples
were considered positive for GAD autoantibodies; one schizophrenia pa-
tient and one control. This suggests that serum GAD autoantibodies at
high titers are very rare (2 out of 621) in schizophrenia-spectrumFig. 2. Rat brain immunohistochemistry (IHC) for GAD+ cases. Case 1 shows a typical GAD65+
shows unknown binding pattern of serum with GAD67 autoantibodies. More details of cases c
466disorders. A previous meta-analysis on the prevalence of GAD autoanti-
bodies in patients with psychosis reported that patients weremore likely
to have GAD65 antibodies than controls (odds ratio [OR], 2.24; 95%CI:
1.28–3.92%; P=0.005; eight studies; I2 = 0%) with a pooled prevalence
of 5.8% (Grain et al., 2017). However, previous studies were using the
more sensitive radio immuno assay (RIA), radio immunoprecipitation/67+ antibody binding pattern similar to serum from a patientwith GAD+epilepsy. Case 6
an be found in Table 3.
Table 3
Characteristics of patients with positive CBA results.
CBA resulta Conc. Diagnoses Age Sex IHC gradeb
(UM/IDIBAPS)
Correlating patternc Combined conclusiond
Case 1 GAD65/67 1:6400 Schizophrenia 43 f 3/pos. Yes GAD65/67
Case 2 GAD65/67 1:3200 Controle 59 m 2/NA Yes GAD65/67
Case 3 GAD67 1:100 Schizophrenia 31 f 1/neg. No ND
Case 4 GAD67 1:100 Controle 55 f 1/neg. No ND
Case 5 GAD67 1:200 Psychosis NOS 32 m 1/neg. No ND
Case 6 GAD67 1:100 Controle 68 m 2/pos. No ND
Conc. = highest still positive serum concentration, UM= Maastricht University, IDIBAPS = Institut d'investigacions Biomèdiques August Pi i Sunyer, ND = not determined.
a CBA for GAD was performed on fixed cells.
b IHC at UM was graded 0–3 and at IDIBAPS positive/negative.
c Indicates whether the IHC hippocampal pattern resembled the typical pattern of the antigen identified by CBA.
d A conclusion was drawn based on the combination of different methods. Only, if a sera was tested positive by CBA and the IHC pattern correlated with the CBA results, it was con-
sidered positive.
e Controls consisted of blood donors and individuals without psychiatric diagnosis.
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reported results likely included also the lower antibody titers. From our
unpublished studies, we know that the CBA and IHC detect GAD antibod-
ies of higher titer and we expected higher titers to be more relevant for
autoimmune-related neurological diseases while low titers are usually a
diagnostic marker for diabetes mellitus type 1. A diagnosis of diabetes,
however, was not excluded, which is a confounding factor, especially be-
cause patients with schizophrenia have a higher risk for comorbid diabe-
tes mellitus type 1 (Benros et al., 2014b).
None of the patients in our study had a registered diagnosis of SLE,
though we detected autoantibodies to specific SLE related antigens in 3
patients. Further clinical assessment of these patients would be necessary
to determine a possible diagnosis of SLE. SARD-related autoantibodies,
particularly those in SLE, have been associated with the occurrence of
neuropsychiatric symptoms, also referred to as neuropsychiatric lupus
(NPSLE) (Tay and Mak, 2017) whereby the most common symptoms
are depression, cognitive dysfunction and anxiety. The reported preva-
lence of psychosis in SLE varies greatly depending on the population
with 2.3% in an English population (Pego-Reigosa and Isenberg, 2008),
and up to 11% in a black Caribbean study population (Flower et al.,
2017). Little has been reported on the prevalence of SLE in patients with
schizophrenia spectrum disorders. In the overall population of Europe
the prevalence is estimated to be 35/100000 and 110/100000 in Afro-
Caribbean people (Rees et al., 2017). In a large Danish National Register
study of 7704 schizophrenia patients, nonewas reportedwith a diagnosis
of SLE (Eaton et al., 2006). Yet, cases of patients presenting with a psy-
chotic disorder or atypical SLE with predominant psychiatric manifesta-
tions have been described before (Lungen et al., 2019; Mack et al.,
2017) and raise the question whether atypical presentation of SLE
might hamper the diagnosis in patients presenting with psychotic disor-
ders. In these cases, psychiatric symptoms might represent a prodromal
stage of the disease or a subtype of SLE with isolated CNS involvement.
Marrie et al. found that the incidence of psychiatric comorbidity is ele-
vated in the immune-mediated inflammatory diseases (IMID) population
(such as inflammatory bowel disease, multiple sclerosis and rheumatoid
arthritis) as compared with a matched population as early as 5 years
before diagnosis (Marrie et al., 2019). Whether this reflects shared risk
factors for psychiatric disorders and IMID, a shared final common inflam-
matory pathway or other etiology is still matter of debate.
In the last 10 years, 16 novel autoimmune diseases of the CNS have
been identified, leading to new treatment strategies for neurological
and psychiatric syndromes (Dalmau et al., 2017). However, our previous
studies (de Witte et al., 2015; Hoffmann et al., 2019) indicate that the
prevalence of NSAbs is very low in patients with psychotic disorders
and not different from the prevalence in control populations. It should
be mentioned however, that the percentage of patients with an
autoimmune origin of the disease might still be larger, but the tested
autoimmune antibodies are signs of specific disorders that only affect a
small number of individuals. It was our strategy to select a very467heterogeneous population to represent a wide spectrum of patients.
Treatment-resistant and acute/recent onset patients have been reported
to have a higher prevalence of known autoimmune encephalitis-related
autoantibodies (Pollak et al., 2019). Whether this is also the case for po-
tentially novel antigens or SARD-related autoimmunity remains to be
shown.
Our finding of reactive autoantibodies to rat brainwarrants further re-
search for the identification of the antigen as their target. As most of the
serawere not reactive to live neurons, they potentially target intracellular
or glial antigens. Neuronal surface receptors and channels have a high ho-
mology between rat and human so rat tissue can be used for detection of
most human antibodies against these antigens. Some antigens however,
e.g. dopamine receptor 2 are not detected by rat brain IHC. Especially
when considering that novel antigens might be targeted in psychotic pa-
tients, one has to be aware that thesemight bemissedwhen using the rat
brain IHC. Also, we confirmed neuronal specificity on primary cultured
life neurons, but we cannot exclude that (i) some neuronal antigens are
expressed at a very low level in the cultured environment, or (ii) somean-
tibodies target other cell types, e.g. microglia or astrocytes. Finally, a com-
bination of serum analysis with cerebrospinal fluid (CSF) is always
desirable as thepresence of intrathecal antibodies increases the likelihood
for disease relevance. Some antibodies, such as anti-NMDAR are better
detectable in CSF, whereas others, such as those targeting LGI-1 and
AQP4 might only be detectable in serum (Graus et al., 2016). General
CSF analysis including white blood cell count, oligoclonal bands, and
protein concentration can give further indications of increased intrathecal
inflammation. CSF and serum analysis in 456 patients with
schizophreniform syndromes also found that established anti-neuronal
IgG antibodies are rare in serum (Endres et al., 2020). The study further
reports, that antibodies are even rarer in the CSF but CSF alterations re-
vealed a substantial subgroup with neuroinflammatory signs.
5. Conclusion
Autoantibodies against nuclear antigens, cardiolipin and GAD are
rare in psychotic disorders. Serum reactivity on brain tissue indicates
antibodies binding to unidentified antigens and future studies should
thus focus on the identification of potentially novel antigens, including
those targeting microglia and astrocytes as well as their disease rele-
vance. The occurrence of SLE-related autoantibodies in 3 patients with
schizophrenia-spectrum disorders warrants further research into the
prevalence of atypical (undiagnosed) SLE in psychiatric disorders as
well as whether psychotic symptoms are increased in the years preced-
ing a diagnosis of SLE. The role of T-cell autoimmunity has not been ad-
dressed in our study but might represent an important pathogenic
mechanism. Additionally, a better characterization of the patient cohort
including neurological and general CSF examination is desirable to in-
crease the chance of identifying individuals with an autoimmune origin
of the disease.
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Three cases with comorbid anti-nuclear autoantibodies specific to systemic lupus erythematosus.Diagnose Age Sex Illness duration (yrs.) ELISAANA IFA ANA dsDNA RPP CLchizophrenia (paranoid type) 39 Male 0.5 + + − + + (IgG)
chizoaffective disorder 23 Female 8 + + + − +
chizophrenia (paranoid type) 21 Female 4.9 + − − + + (IgA)SELISA=enzyme-linked immunosorbent assay, RPP= ribosomal protein P, dsDNA=double-stranded deoxyribonucleic acid, ANA=anti-nuclear antibodies, CL= cardiolipin, ANA IFA=
immunofluorescence on HEp-2 substrate for detection of antinuclear antibodies.References
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